Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.46, sa.6, ss.1787-1791, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 46 Sayı: 6
- Basım Tarihi: 2021
- Doi Numarası: 10.1111/jcpt.13364
- Dergi Adı: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
- Sayfa Sayıları: ss.1787-1791
- Anahtar Kelimeler: atezolizumab, immunotherapy, microsatellite instability, ovarian cancer, PD-L1
- İstanbul Üniversitesi Adresli: Evet
Özet
What is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab.